UBS Upgrades Sartorius Stedim Biotech to Buy, Boosts PT

08:35 AM EDT, 08/20/2026 (MT Newswires) -- UBS on Thursday upgraded French biopharmaceutical group Sartorius Stedim Biotech (DIM.PA) to buy from neutral and increased its price target to 260 euros from 220 euros. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)